生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | c-Jun N-terminal kinase (JNK) is implicated in various human diseases, including cancer, inflammatory disorders, and neurodegeneration. JNK inhibitor IX is a potent JNK inhibitor with pIC50 values of 6.5 and 6.7 for JNK2 and JNK3, respectively[3]. Pre-treatment of human dermal fibroblasts with JNK inhibitor IX (10μM) 30min before chromium exposure significantly reduces caspase-3 activity compared to the group only treated with chromium[4]. Treatment of myeloid cells with JNK inhibitor IX (10μM) for 24 h significantly reduced JNK phosphorylation and increased apoptotic cell death in response to imatinib mesylate[5]. | ||
作用机制 | JNK inhibitor IX is a potent, ATP-competitive inhibitor of both JNK2 and JNK3[3]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.01mL 0.60mL 0.30mL |
15.04mL 3.01mL 1.50mL |
30.08mL 6.02mL 3.01mL |
参考文献 |
---|